Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 3 institutions in 1 country.
Darby GilfillanDepartment of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0001-6445-4165
Allison C VilanderDepartment of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
Meichen PanDepartment of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Raleigh, NC 27695, USA.ORCID 0000-0003-0495-4365
Yong Jun GohDepartment of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Raleigh, NC 27695, USA.ORCID 0000-0001-7998-8469
Sarah O'FlahertyDepartment of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Raleigh, NC 27695, USA.ORCID 0000-0001-8629-0675
Ningguo FengDepartments of Medicine and Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Bridget E FoxDepartment of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0003-1327-6594
Callie LangDepartment of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
Harry B GreenbergDepartments of Medicine and Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Zaid AbdoDepartment of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0002-8272-7734
Rodolphe BarrangouDepartment of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Raleigh, NC 27695, USA.ORCID 0000-0002-0648-3504
Gregg A DeanDepartment of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0001-7025-9550
Colorado State University · USNorth Carolina State University · USVA Palo Alto Health Care System · US
Funding
Biomedical Research Training for VeterinariansT32OD010437 · OD · COLORADO STATE UNIVERSITY · PI Gregg A Dean, KELLY S SANTANGELO · 2012 to 2026
$6.2M
Novel recombinant Rotavirus vaccine utilizing the probiotic microorganism Lactobacillus acidophilusR01AI141603 · NIAID · COLORADO STATE UNIVERSITY · PI ABDO, ZAID, BARRANGOU, RODOLPHE · 2020 to 2024
$3.6M
CSU Infectious Disease Research and Response Training ProgramT32AI162691 · NIAID · COLORADO STATE UNIVERSITY · PI DEAN, GREGG A · 2021 to 2025
Rotavirus diarrhea-associated illness remains a major cause of global death in children under five, attributable in part to discrepancies in vaccine performance between high- and low-middle-income countries. Next-generation probiotic vaccines could help bridge this efficacy gap. We developed a novel recombinant
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.